The Top 5 Biosimilars Articles for the Week of July 31

Article

The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 31, 2017.

Transcript

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of July 31.

Number 5: A recent survey of Canadian patients highlights serious concerns about automatic substitution of biosimilars for reference products.

Number 4: Biosimilar developer Coherus has moved for a stay of discovery in its BPCIA litigation over pegfilgrastim, citing the company’s need to preserve its resources.

Number 3: The FDA Reauthorization Act of 2017 was passed by the Senate on Thursday. The must-pass bill reauthorizes user fees for biosimilar applicants.

Number 2: It was a busy week for trastuzumab biosimilars, with biologics license applications filed by Amgen and Allergan as well as Celltrion and Teva.

And Number 1: Brian Lehman takes a close look at the potential impact of Merck’s launch of Renflexis at a 35% discount off the list price of the reference, Remicade, in the US marketplace.

Finally, last week, our newsletter asked you to share your thoughts on how great a discount payers are expecting for biosimilar products. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.

To sign up for our weekly newsletter or to read these articles and more, visit www.centerforbiosimilars.com.

Related Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.